Who
Elizabeth H.Z. Thompson
EVP, Head of Research & Dev
Company insider
Files Form 4 as: EVP, Head of Research & Dev, ACADIA Pharmaceuticals; Director, IGM Biosciences; EVP, Research & Development, Horizon Therapeutics Public Ltd Co.
In numbers
- Trades disclosed
- 63
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $3.3M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Jul 2021
- Last trade
- 30 Jul 2026
- Last filed
- 31 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jul 2026filed 31 Jul 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $431K16,508 at $26.13 | filing |
| 30 Jul 2026filed 31 Jul 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1,30950 at $26.17 | filing |
| 30 Jul 2026filed 31 Jul 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $431K16,508 at $26.13 | filing |
| 30 Jul 2026filed 31 Jul 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1,30950 at $26.17 | filing |
| 29 Jul 2026filed 31 Jul 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —32,272 | filing |
| 29 Jul 2026filed 31 Jul 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —32,272 at $0.00 | filing |
| 29 Jul 2026filed 31 Jul 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —32,272 at $0.00 | filing |
| 29 Jul 2026filed 31 Jul 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —32,272 | filing |
| 25 Mar 2026filed 26 Mar 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $74K3,435 at $21.47 | filing |
| 25 Mar 2026filed 26 Mar 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $74K3,435 at $21.47 | filing |
| 24 Mar 2026filed 26 Mar 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —6,715 | filing |
| 24 Mar 2026filed 26 Mar 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,715 at $0.00 | filing |
| 24 Mar 2026filed 26 Mar 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,715 at $0.00 | filing |
| 24 Mar 2026filed 26 Mar 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —6,715 | filing |
| 6 Mar 2026filed 10 Mar 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —101,574 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —29,548 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —101,574 at $0.00 | filing |
| 6 Mar 2026filed 10 Mar 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —29,548 at $0.00 | filing |
| 14 Aug 2025filed 14 Aug 2025 | IGM Biosciences | SEC FORM 4 Code D | —7,196 | filing |
| 30 Jun 2025filed 2 Jul 2025 | IGM Biosciences | SEC FORM 4 Code A | —694 at $0.00 | filing |
News
Head-To-Head Comparison: ACADIA Pharmaceuticals (NASDAQ:ACAD) versus C4 Therapeutics (NASDAQ:CCCC)ACAD · tickerreport.com · 19 Oct 2026Critical Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)ACAD · dailypolitical.com · 15 Oct 2026ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Neutral" at UBS GroupACAD · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Elizabeth H.Z. Thompson; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.